To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 1
This profile is validated by 1 label.

Société

Mitral Technologies

Mitral Technologies_logo
18
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Mitral Technologies is a MedTech company dedicated to the development and marketing of a novel device for the treatment of mitral valve regurgitation through mitral valve repair.

Liège, Belgique, Minnesota, États-Unis

Envoyer un message

  • 4

    Employés

French

Mitral Technologies

French

Mitral Technologies is dedicated to the development and marketing of a novel device to for the treatment of mitral valve regurgitation through mitral valve repair. 

2% of the world population suffers from mitral valve regurgitation mainly as a consequence of heart attack. 9.3% of people 75 years old or more have severe mitral regurgitation (MR).

Mitral Technologies device and procedure will allow physicians to treat mitral regurgitation through a transcatheter...

En savoir plus

Mitral Technologies is dedicated to the development and marketing of a novel device to for the treatment of mitral valve regurgitation through mitral valve repair. 

2% of the world population suffers from mitral valve regurgitation mainly as a consequence of heart attack. 9.3% of people 75 years old or more have severe mitral regurgitation (MR).

Mitral Technologies device and procedure will allow physicians to treat mitral regurgitation through a transcatheter procedure commonly used by interventional cardiologists. Learning curve for this new technology is expected to be minimal because it is based on cardiologist’s standard expertise.

2 million people suffering from MR are not suitable for surgery due to high surgical risks. This population will definitely benefit of transcatheter mitral valve regurgitation repair.  The second group of patients involves the 50% of patients who are denied surgery because of poor left ventricular function that would not survive the one step MR correction because of poor heart function. . These patients will greatly benefit from a transcatheter treatment of MR that progressively reduces the regurgitation in several steps giving to the heart time to adapt (remodel) to a better mitral valve function.

The development of this project is anticipated to take 5 and 1/2 years until CE marking approval. This plan described the research and development, the pre-clinical and clinical testing and the regulatory steps needed to reach CE marking.

  • 1

    Like

Nos actualités

Notre réseau

Votre demande a bien été envoyée
Rejoindre ce réseau
Votre message a bien été envoyé

Labels

ePitches EuroQuity
Label des meilleures start-ups coachées et accompagnées par EuroQuity lors de webconférences. Ces sociétés ont alors présenté leurs projets lors de webinars avec les investisseurs.
172 Organisations

Communautés

EUROQUITY BELGIQUE
UN SERVICE POUR SOUTENIR LA CROISSANCE DES ENTREPRISES La communauté est réservée aux entreprises soutenues par le Groupe Sowalfin, Hub. Brussels et leurs partenaires
160 Membres

Notre histoire

Débute le 01/01/2015

  • 01/01/2015

    L Tozzi & JP Rasschaert gathered to develop a mitral valve regurgitation repair treatment.

  • Apr. 2015

    Patent filing: PCT/US 2014/073084 28 Filed

  • May 2015

    Scientific Advisory board is created with: Pr. Piergiorgio Tozzi,M.D. and Didier Locca, M.D.

à suivre…